Outcomes of Thymic Neoplasms after the 1999 Who Classification
Yousif Yonan,John M. Varlotto,Thomas J. Fitzgerald,Abram Recht,Karl Uy,William Vincent Walsh,John Charles Flickinger,Fei Gu,Geoffrey Graeber,Richard Sawyer Pieters,James Edward Liebmann,Nengliang Yao,Syed Quadri,Suhail M. Ali
DOI: https://doi.org/10.1200/jco.2014.32.15_suppl.7604
IF: 45.3
2014-01-01
Journal of Clinical Oncology
Abstract:7604 Background: In 1999 the World Health Organization (WHO) published a histologic sub-typing system for thymoma that divided it in to six classes, which included one category for thymic carcinoma (WHO C, Group 1) and five categories of invasive thymoma (WHO A, AB, B1, B2 and B3, Group 2). Methods: The SEER database was used to retrospectively identify thymic neoplasms from 2000-2010 using the six-tier classification system. Only those patients having thymic neoplasia as their only cancer and undergoing complete (R0) resection were included in the analysis. Overall survival (OS) and thymic-specific survival (TSS) were evaluated by Kaplan-Meier methods. Multivariate analysis(MVA) was performed including group, age, race, Masaoka stage, gender, and adjuvant radiation therapy as key variables. Results: 505 thymic neoplasms were identified including 96 (19%) in group 1 and 409 (81%) in group 2. Median follow-up was 38 months. For patients with early Stage(I/II) group 1 and group 2 tumors, OS at 2, 3, and 5 years was 90.5, 90.5, 67.9% for Group 1 and 98.2, 95.8, 95.8 for Group 2 respectively. Group 1 classication (p<0.0001, HR 1.82), advancing age (p=0.003, HR 1.03) and increasing stage (p=0.04, HR 1.37) were significant predictors of worse OS. TSS was excellent in the overall group with thymus-related death listed as cause of death in only 35 (6.9%) of patients. Any Group 1 and Stage III/IV Group 2 tumors had significantly worse TSS. Histologic sub-typing within Group 2 was not associated with OS, TSS or high-risk of lymph node involvement (all<5%). In early-stage Group 1 patients, 15/34 (44%) did not have a nodal exam and 6/19 (32%) had positive nodes. Conclusions: Early-stage Group 2 patients have an excellent OS and TSS may not benefit from adjuvant therapy. Trials of adjuvant therapy should be considered for advanced-stage Group 2 patients and all Group 1 patients. Thymic carcinomas may be understaged due to lack of lymph node examination and the high percentage with involved nodes.